Want to see TKNO full AI Analyst Report?
TKNO Stock Chart & Stats
$7.22
-$0.12(-2.41%)
At close: 4:00 PM EDT
$7.22
-$0.12(-2.41%)
Day’s Range― - ―
52-Week Range$1.91 - $9.48
Previous Close$4.85
Volume119.72K
Average Volume (3M)249.59K
Market Cap
$474.60M
Enterprise Value$314.62M
Total Cash (Recent Filing)$17.44M
Total Debt (Recent Filing)$27.41M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding53,688,248
10 Day Avg. Volume312,344
30 Day Avg. Volume249,588
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-20.75
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue7.20
Enterprise Value/Gross Profit21.21
Enterprise Value/Ebitda-33.25
Forecast
1Y Price Target
$8.50Price Target Upside17.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$45.95M
Bulls Say, Bears Say
Bulls Say
Broad Life-Science ApplicationsAlpha Teknova serves multiple research, diagnostic, and biomanufacturing applications rather than relying on one narrow use case. This breadth can diversify demand, expand cross-selling opportunities, and position its reagents as recurring inputs across customers’ development and production workflows.
Revenue And Loss Trend ImprovementRevenue is still growing modestly, and the substantial improvement from earlier loss levels indicates operating performance is moving in the right direction. Continued top-line expansion combined with further efficiency gains could improve the company’s path toward breakeven over the coming quarters.
Manageable LeverageDebt remains moderate relative to the reported equity base, giving Alpha Teknova more financial flexibility than a highly leveraged business. This balance-sheet position may provide capacity to support operations and growth while management works to improve profitability and cash generation.
Bears Say
Persistent UnprofitabilityThe company remains deeply unprofitable at both the operating and net-income levels, so revenue growth has not yet translated into sustainable earnings. Until margins improve materially, Alpha Teknova may have limited ability to fund expansion internally or demonstrate durable operating leverage.
Negative Cash GenerationOngoing operating and free-cash-flow losses show that the business is not yet self-funding, even though cash burn has improved from 2022–2023. Continued negative generation can require balance-sheet resources or external financing, reducing flexibility for investment and execution.
Shrinking Equity CushionDeclining equity and strongly negative returns indicate that losses are eroding the company’s capital base rather than creating shareholder value. If this pattern persists, the shrinking cushion could reduce financial resilience and make future funding needs more consequential for the business.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $1.91 and its highest was $9.48 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $474.60M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Nov 05, 2026 which is in 23 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Aug 05, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.024.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.07.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,688,248 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 16.399%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Teknova Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (17.73% Upside)
$8.50 (17.73% Upside)
Blogger Sentiment
Neutral
TKNO Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 592.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.04%
12-Months-Change
Fundamentals
Return on Equity
-24.94%
Trailing 12-Months
Asset Growth
-13.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alpha Teknova
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: the company reported solid top-line growth (13% YoY), a pronounced 85% increase in Clinical Solutions, improved gross margin and adjusted EBITDA, operational scaling initiatives, and disciplined commercial investments aimed at driving ~20% growth in 2027. However, material risks remain including a persistent GAAP net loss, continued negative adjusted EBITDA, modest Lab Essentials growth, high fixed-cost structure with a roughly 70% marginal cash drop-through, and dependence on broader biotech funding recovery. Management reiterated a conservative 2026 guide while outlining a credible plan for improved profitability and growth in 2027.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$8.50
▲(17.73% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Evotec AG
―
Organogenesis Holdings
―
Eton Pharmaceuticals
―
Ownership Overview
1.31% Insiders
2.50% Mutual Funds
7.24% Other Institutional Investors
84.41% Public Companies and
Individual Investors